Showing results (31-40 of 181) with videos related to

Sort By:
Pageof 19
ACR Open Rheumatology|April 9, 2020
Comparative Risk of Diabetes Mellitus in Patients With Rheumatoid Arthritis Treated With Biologic or Targeted Synthetic Disease-Modifying Drugs: A Cohort StudyRishi J Desai, Sara Dejene, Yinzhu Jin, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 2, 2021
Risk of Serious Infections With Vedolizumab Versus Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel DiseaseJulien Kirchgesner, Rishi J Desai, Laurent Beaugerie, et al.
Pharmacoepidemiology and Drug Safety|May 28, 2016
Validation of claims-based algorithms for gout flaresLindsey A MacFarlane, Chih-Chin Liu, Daniel H Solomon, et al.
ACR Open Rheumatology|July 1, 2021
Comparative Risk of Nonvertebral Fractures Among Patients With Rheumatoid Arthritis Treated With Biologic or Targeted Synthetic Disease-Modifying Antirheumatic DrugsAjinkya Pawar, Rishi J Desai, Mengdong He, et al.
Seminars in Arthritis and Rheumatism|August 17, 2021
The risk of serious infection in rheumatoid arthritis patients receiving tocilizumab compared with tumor necrosis factor inhibitors in KoreaHa-Lim Jeon, Seoyoung C Kim, So-Hee Park, et al.
Rheumatology Advances in Practice|September 11, 2020
Use of biologic or targeted-synthetic disease-modifying anti-rheumatic drugs and risk of diabetes treatment intensification in patients with rheumatoid arthritis and diabetes mellitusSarah K Chen, Hemin Lee, Yinzhu Jin, et al.
JAMA Dermatology|May 11, 2019
Risk of Serious Infection in Patients Receiving Systemic Medications for the Treatment of PsoriasisErica D Dommasch, Seoyoung C Kim, Moa P Lee, et al.
Cardiovascular Diabetology|March 24, 2022
Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysisArnaud D Kaze, Min Zhuo, Seoyoung C Kim, et al.
Arthritis and Rheumatism|July 12, 2012
No differences in cancer screening rates in patients with rheumatoid arthritis compared to the general populationSeoyoung C Kim, Sebastian Schneeweiss, Jessica A Myers, et al.
The Journal of Rheumatology|May 17, 2018
Cardiovascular (CV) Risk after Initiation of Abatacept versus TNF Inhibitors in Rheumatoid Arthritis Patients with and without Baseline CV DiseaseYinzhu Jin, Eun Ha Kang, Gregory Brill, et al.
Pageof 19